PHE Expert Shafrin: Make Real-World Evidence the New Gold Standard


In an in-depth commentary for Pharmaceutical Market Europe, senior economist Jason Shafrin argues for real-world evidence (RWE) to become the “gold standard” of scientific evidence and heath technology assessments. RWE provides an opportunity to accelerate drug approval, monitor treatment safety, and appropriately price medications, Shafrin writes.

To read Jason’s complete commentary, please click here. (pg. 18-19)


Precision Medicine Group is an integrated team of experts in fields from advanced lab sciences to translational informatics and regulatory affairs, payer insights to marketing communications. Together, we help our pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.